Ann: 2011 Annual Report , page-2

There is so much in this report, we will discuss the implications of this report for some time to come, I'm sure.

What stands out massively at first reading is the fact the first FMCG consumer acceptance testing was indeed so positive that another healthcare company wishes to progress as well.
Keep in mind that some posters here were arguing wether the FMCG had indeed cancelled collaborations.


The other massive point is that in vivo testing for GSK has exceeded in vitro testing.

In the more lucrative medium to long-term Pharmaceutical and Healthcare sectors, we were pleased to announce
in May this year our securing of a collaborative research and development agreement with GSK Healthcare. Since
the announcement, further and more compelling data has been generated. Both static and FIM magnetic arrays -
and in vivo clinical studies are now well advanced.

We now know that in vivo studies are not only well advanced but also exceeded the invitro studies which were already significant.
We also now know that GSK uses static as well as FIM magnetic arrays for their products. We are looking at a whole range of products in the making there.


Had we speculated that the FMCG1 was close to an announcement, it is fair to say that interest from another global healthcare company will only push this contract along quicker.

Im very impressed with the whole range of revelations in this report.